SNT 0.00% 4.3¢ syntara limited

Ann: Nature Cancer Publishes Results of PXS Garvin Collaboration, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,802 Posts.
    lightbulb Created with Sketch. 706
    equity raise unlikely due to the bridging loan before R&D tax benefit is received

    the real concern and why I believe the selling from Gary and others has been so staunch is because of the news from GSK on their FDA approved myelofibrosis drug

    https://pharmaphorum.com/news/gsk-gets-wide-fda-approval-myelofibrosis-drug

    PXS great but slow, Big Pharma appears to be working more in-house and only making big investments when significant positive data and analysis is produced by small biotechs for high commercial targets
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
4.3¢
Change
0.000(0.00%)
Mkt cap ! $59.04M
Open High Low Value Volume
4.3¢ 4.3¢ 4.2¢ $20.22K 474.7K

Buyers (Bids)

No. Vol. Price($)
1 25780 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.4¢ 581744 4
View Market Depth
Last trade - 15.54pm 11/10/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.